Correlation Between Pharvaris and AN2 Therapeutics

Can any of the company-specific risk be diversified away by investing in both Pharvaris and AN2 Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Pharvaris and AN2 Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Pharvaris BV and AN2 Therapeutics, you can compare the effects of market volatilities on Pharvaris and AN2 Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Pharvaris with a short position of AN2 Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Pharvaris and AN2 Therapeutics.

Diversification Opportunities for Pharvaris and AN2 Therapeutics

0.33

Correlation Coefficient

Pharvaris  AN2 Therapeutics

Weak diversification

The 3 months correlation between Pharvaris and AN2 is 0.33. Overlapping area represents the amount of risk that can be diversified away by holding Pharvaris BV and AN2 Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on AN2 Therapeutics and Pharvaris is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Pharvaris BV are associated (or correlated) with AN2 Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of AN2 Therapeutics has no effect on the direction of Pharvaris i.e., Pharvaris and AN2 Therapeutics go up and down completely randomly.

Pair Corralation between Pharvaris and AN2 Therapeutics

Given the investment horizon of 90 days Pharvaris is expected to generate 1.75 times less return on investment than AN2 Therapeutics. But when comparing it to its historical volatility, Pharvaris BV is 1.12 times less risky than AN2 Therapeutics. It trades about 0.11 of its potential returns per unit of risk. AN2 Therapeutics is currently generating about 0.17 of returns per unit of risk over similar time horizon. If you would invest  110.00  in AN2 Therapeutics on September 3, 2024 and sell it today you would earn a total of  57.00  from holding AN2 Therapeutics or generate 51.82% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Pharvaris BV  vs.  AN2 Therapeutics

Pharvaris BV

Risk-Adjusted Performance

8 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Pharvaris BV are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Pharvaris unveiled solid returns over the last few months and may actually be approaching a breakup point.

AN2 Therapeutics

Risk-Adjusted Performance

13 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in AN2 Therapeutics are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, AN2 Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Pharvaris and AN2 Therapeutics

The main advantage of trading using opposite Pharvaris and AN2 Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Pharvaris position performs unexpectedly, AN2 Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AN2 Therapeutics will offset losses from the drop in AN2 Therapeutics' long position.

The idea behind Pharvaris BV and AN2 Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.